Advanced search
Publication Cover
Expert Review of Vaccines Volume 15, 2016 - Issue 4: Dengue Vaccines
Submit an article Journal homepage
1,971
Views
8
CrossRef citations to date
0
Altmetric
Editorial

Edging closer towards the goal of a dengue vaccine

Annelies Wilder-SmithLee Kong Chian School of Medicine, Nanyang Technological University Singapore;Dengue Vaccine Initiative, International Vaccine Institute, Seoul, KoreaCorrespondence[email protected]
View further author information
&
In-Kyu YoonDengue Vaccine Initiative, International Vaccine Institute, Seoul, KoreaView further author information
Pages 433-435 | Received 05 Oct 2015, Accepted 11 Feb 2016, Published online: 17 Mar 2016

References

  • Murray NE, Quam MB, Wilder-Smith A. Epidemiology of dengue: past, present and future prospects. Clin Epidemiol. 2013;5:299–309.
  • Horstick O, Tozan Y, Wilder-Smith A. Reviewing dengue: Still a neglected tropical disease? PLoS Negl Trop Dis. 2015;9(4):e0003632.
  • Thomas SJ, Endy TP. Current issues in dengue vaccination. Curr Opin Infect Dis. 2013;26(5):429–434.
  • Guy B, Saville M, Lang J. Development of Sanofi Pasteur tetravalent dengue vaccine. Human Vaccines. 2010;6(9):696–705.
  • Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373(13):1195–1206.
  • Wilder-Smith A, Massad E. Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine. Expert Rev Vaccines. 2016;15(4):437–441.
  • Leo YS, Wilder-Smith A, Archuleta S, et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore. Hum Vaccin Immunother. 2012;8(9):1259–1271.
  • Beatty PR, Puerta-Guardo H, Killingbeck SS, et al. Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. Sci Transl Med. 2015;7(304):304ra141.
  • Rivino L. T cell immunity during dengue virus infection and implications for vaccine design. Expert Rev Vaccines. 2016;15(4):443–453.
  • Rivino L, Kumaran EA, Thein TL, et al. Virus-specific T lymphocytes home to the skin during natural dengue infection. Sci Transl Med. 2015;7(278):278ra35.
  • Weiskopf D, Angelo MA, de Azeredo EL, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A. 2013;110(22):E2046–53.
  • Osorio JE, Wallace D, Stinchcomb DT. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. Expert Rev Vaccines. 2016;15(4):497–508.
  • Whitehead SS. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine? Expert Rev Vaccines. 2016;15(4):509–517.
  • Lam JH, Ong LC, Alonso S. Key concepts, strategies, and challenges in Dengue vaccine development: An opportunity for sub-unit candidates? Expert Rev Vaccines. 2016;15(4):483–495.
  • Dejnirattisai W, Wongwiwat W, Supasa S, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol. 2015;16(2):170–177.
  • Acosta EG, Bartenschlager R. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development. Expert Rev Vaccines. 2016;15(4):467–482.
  • Srikiatkhachorn A, Yoon IK. Immune correlates for dengue vaccine development. Expert Rev Vaccines. 2016;15(4):455–465.
  • Hajjeh RA, Privor-Dumm L, Edmond K, et al. Supporting new vaccine introduction decisions: lessons learned from the Hib Initiative experience. Vaccine. 2010;28(43):7123–7129.
  • Lim JK, Lee YS, Wilder-Smith A, et al. Points for consideration for dengue vaccine introduction – recommendations by the dengue vaccine initiative. Expert Rev Vaccines. 2016;15(4):529–538.
  • Constenla D, Clark S. Financing dengue vaccine introduction in the Americas: challenges and opportunities. Expert Rev Vaccines. 2016;15(4):447–459.
  • Carvalho A, Van Roy R, Andrus J. International Dengue Vaccine Communication and Advocacy: challenges and Way Forward. Expert Rev Vaccines. 2016;15(4):539–545.
  • Tozan Y. Current issues in the economics of vaccination against dengue. Expert Rev Vaccines. 2016;15(4):519–528.
  • Wilder-Smith A, Gubler DJ. PUBLIC HEALTH. Dengue vaccines at a crossroad. Science. 2015;350(6261):626–627.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.